Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>CYP2C9</i> and <i>HLA‐B</i> Genotypes and Phenytoin Dosing: 2020 Update
Jason H. Karnes(University of Arizona), Allan E. Rettie(University of Washington), Andrew A. Somogyi(The University of Adelaide), Rachel Huddart(Stanford University), Alison E. Fohner(University of Washington), Christine M. Formea(Intermountain Healthcare), Ming Ta Michael Lee(Geisinger Health System), Adrián LLerena(Government of Extremadura), Michelle Whirl‐Carrillo(Stanford University), Teri E. Klein(Stanford University), Elizabeth J. Phillips(Vanderbilt University Medical Center), Scott Mintzer(Thomas Jefferson University Hospital), Andrea Gaedigk(Children's Mercy Hospital), Kelly E. Caudle(St. Jude Children's Research Hospital), John T. Callaghan(Indiana University School of Medicine)
Cited by 170Open Access
Abstract
Phenytoin is an antiepileptic drug with a narrow therapeutic index and large interpatient pharmacokinetic variability, partly due to genetic variation in CYP2C9. Furthermore, the variant allele HLA-B*15:02 is associated with an increased risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in response to phenytoin treatment. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for the use of phenytoin based on CYP2C9 and/or HLA-B genotypes (updates on cpicpgx.org).
Related Papers
No related papers found
Powered by citation graph analysis